Updated treatment flow and patterns for people with ulcerative colitis
Describing Prescription Patterns in an Ulcerative Colitis Population and Generating an Updated Ulcerative Colitis Treatment Paradigm
This project will look at treatment patterns to see if earlier switching to advanced therapies helps people with poorly controlled ulcerative colitis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Tadworth) |
| Trial ID | NCT07177209 on ClinicalTrials.gov |
What this trial studies
This observational analysis uses longitudinal patient data from an inflammatory bowel disease registry starting in 2009 to map real-world treatment patterns in adults with ulcerative colitis. Researchers will identify cohorts by follow-up duration and disease control and describe timing and frequency of switches to advanced therapies. The study is non-interventional and relies on existing medical records and registry entries with minimum six-month follow-up for included cohorts. Outcomes include measures of inflammation control and long-term disease outcomes associated with earlier versus later switching to advanced treatments.
Who should consider this trial
Good fit: Adults diagnosed with ulcerative colitis who are enrolled in the IBD registry (records from 2009 onward) and have at least six months of post-diagnosis data are ideal candidates.
Not a fit: Patients without registry records, people with well-controlled disease who never required escalation, or those diagnosed as children are unlikely to benefit directly from this analysis.
Why it matters
Potential benefit: If successful, the findings could help doctors decide whether switching to advanced therapies earlier reduces inflammation and long-term complications.
How similar studies have performed: Previous registry and cohort studies have informed treatment pathways and some clinical trials suggest earlier use of biologics can improve outcomes, but consensus is still developing.
Eligibility criteria
Show full inclusion / exclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patient enrolled in IBD registry from 2009 2. \>18 years at time of diagnosis. 3. Diagnosis of Ulcerative Colitis. 4. Patient data entered during the study period. 5. Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)
Where this trial is running
Tadworth
- Pfizer — Tadworth, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.